secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOTRICITY INC. (BTCY)
CIK:        0001630113
Form:       8-K
Filed at:   2022-07-18T23:59:59+00:00
Accession:  0001493152-22-019487
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biotricity reports FY22 revenue $7.7M (+126% YoY); Q4 revenue $2.15M (+81%); net loss $30.2M
--------------------------------------------------------------------------------

- FY22 revenue $7.7M (+126% YoY); gross margin improved to 60% from 38% in FY21.
- Q4 FY22 revenue $2.15M (+81% YoY); gross margin 67% vs 60% in Q4 FY21.
- FY22 net loss $30.2M ($0.665 per share); adjusted loss per share $0.48.
- Cash $12M at March 31, 2022; closed $12M non-convertible debt and extinguished $1.6M legacy debt.
- Expanded network to 300+ centers, 1,500 cardiologists; launched Biotres, Bioheart, Biokit after FDA clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630113/000149315222019487/0001493152-22-019487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630113/000149315222019487/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-019487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer